Deal Watch: Sanofi Further Opts Out Of CNS Tie-Up With Voyager
Sanofi returns two partnered assets to Voyager, further unraveling 2015 deal. Celgene drops Mereo cancer candidate ahead of merger with Bristol, while Ultragenyx and Arcturus expand their joint rare disease efforts.
You may also be interested in...
Partnership will use Carna’s proprietary lipid kinase drug discovery platform, bringing another aspect to Gilead’s IO efforts. Catalent continues expansion by acquiring Novavax R&D assets; Genfit licenses elafibranor in China to Terns.
Bristol-Myers will have to divest Celgene's blockbuster psoriasis pill to address concerns raised by the US FTC related to the merger. The news raised questions about whether FTC is giving more scrutiny to pipeline overlap.
Gilead is elbowing its way into the protein degradation field, seeking to build out a pipeline of oncology drugs in a $45m deal with Nurix. The pool is becoming crowded though, as many other big firms have latched onto this burgeoning field of R&D.